Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Ministries Issue Three-Year Plan To Raise Milk Regulatory Standards In Aftermath Of Melamine Scandal

This article was originally published in PharmAsia News

Executive Summary

BEIJING - To revive public confidence in China's dairy supplies following a nationwide scandal involving the adulteration of milk with the toxic chemical melamine, the central government has unveiled a three-year plan to raise production, inspection and regulatory standards
Advertisement

Related Content

U.S. Pharmacopeia Offers Help In Aftermath Of China's New Scandal, Cover-up Involving Deliberate Adulteration
U.S. Pharmacopeia Offers Help In Aftermath Of China's New Scandal, Cover-up Involving Deliberate Adulteration
A Year After Chinese Health Authorities Vow To Rid Country Of Deliberately Adulterated Milk, A New Melamine Scandal Surfaces
A Year After Chinese Health Authorities Vow To Rid Country Of Deliberately Adulterated Milk, A New Melamine Scandal Surfaces
U.S. FDA Launches First Overseas Office in Beijing
U.S. FDA Launches First Overseas Office in Beijing
Advertisement
UsernamePublicRestriction

Register

SC067400

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel